Company Snapshot

Investment Thesis

Amgen combines a resilient biologics base with new cardiometabolic, oncology, and rare disease assets. Obesity and cardiovascular programs build on scale manufacturing, while Horizon integration broadens the rare disease footprint and extends growth visibility.

  • Cardiometabolic Pipeline: AMG 133 (MariTide) and AMG 786 target obesity and metabolic disease with differentiated dosing schedules.
  • Biosimilar Scale: Global biosimilar launches in oncology and immunology add high-margin revenue streams as legacy products mature.
  • Balance Sheet Discipline: Strong free cash flow supports dividend growth, debt paydown, and continued business development post-Horizon deal.

Revenue Mix

Oncology 36% of FY24 revenue
Cardiovascular & Bone 23% — Repatha, Prolia, Evenity
Inflammation 18% — Enbrel, Otezla
Rare Disease & Other 23% — Horizon portfolio, biosimilars

Mix reflects Amgen fiscal year 2024 segment disclosures post-Horizon acquisition.

Recent Performance

MTD -0.72%
QTD -0.75%
YTD +14.27%
5Y +28.63%

Amgen eased to $291 as investors weighed obesity pipeline timelines against near-term integration costs, though the stock remains up 12% year to date with Horizon accretion and biosimilar launches cushioning earnings.

Strategic Insights

Obesity Optionality

Once-weekly AMG 133 aims to deliver durable weight loss with potentially fewer gastrointestinal side effects, expanding Amgen’s metabolic addressable market.

Biosimilar Execution

Amgen leverages biologics manufacturing to scale oncology biosimilars such as Amjevita and strengthen payer relationships.

Horizon Synergies

Tepezza, Krystexxa, and Uplizna add durable rare disease cash flows while commercial synergies and shared field forces expand specialist reach.

Latest Coverage

Curated headlines sourced from Maxim’s AI newsroom.

Loading latest coverage...